Cerebral Innovations
Saint Petersburg, United States (US) · Health and Medical
Do your work at Cerebral Innovations?
Claim this profile to manage your company.
Verified by Enterprise League
Data quality
Complete · Accuracy
Last verified
May 2026
#fda
#clinical outcome assessments
#coa
#digitized spiral drawing
#type c feedback
#21 cfr part 11
#patient focused drug development
#ai
#parkinson's disease
#essential tremor
Overview
We employ modern computerized endpoints into clinical trials to increase treatment effect sensitivity, thus improving your odds of a successful clinical trial.
What sets Cerebral Innovations apart is our commitment to regulatory-grade, objective digital endpoints, compliant with 21 CFR Part 11, EU GMP Annex 11, and GxP standards. Our platform, NeuroQuantix, standardizes 35+ years of published spiral analysis research into a single endpoint platform, offering pre-specified, defensible endpoints for Phase 2/3 efficacy trials and enabling powered studies with fewer subjects.
NeuroQuantix provides the objective, quantitative motor endpoints across 23 neurological conditions that clinical trials demand and regulators increasingly expect, offering solutions for Phase 1-2 de-risking, gene therapy, rare disease studies, drug safety monitoring, and natural history studies.
Contact Details
Saint Petersburg, United States (US)
Company Type
Private Limited Company
Employees
2-10
Categories
Keywords
#fda
#clinical outcome assessments
#coa
#digitized spiral drawing
#type c feedback
#21 cfr part 11
#patient focused drug development
#ai
#parkinson's disease
#essential tremor
Listings
Companies teams usually look at after Cerebral Innovations
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.